Aeglea Bio Therapeutics Inc
Change company Symbol lookup
Select an option...
AGLE Aeglea Bio Therapeutics Inc
GLBL Cartesian Growth Corp
MRNA Moderna Inc
SPUS.NV SP Funds S&P 500 Sharia Industry Exclusions ETF
EMCF Emclaire Financial Corp
SHOO Steven Madden Ltd
SEGI Sycamore Entertainment Group Inc
KVLQF ValOre Metals Corp
TLLZF Gold Line Resources Ltd
RIGMF Ridgestone Mining Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. It is focused on human enzyme therapeutics to treat people with rare metabolic diseases. Its lead product candidate is pegzilarginase, which is a recombinant human arginase 1 that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase 1 Deficiency. It has engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. Its second product candidate, AGLE-177, is a novel PEGylated ( polyethylene glycol) human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria. The Company is evaluating Pegzilarginase in a global pivotal Phase III pivotal PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and Phase I/II open-label extension trial. It is also conducting a Phase I/II clinical trial for the treatment of patients with Homocystinuria.

Closing Price
$1.57
Day's Change
0.02 (1.29%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.59
Day's Low
1.47
Volume
(Light)
Volume:
112,507

10-day average volume:
321,528
112,507

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.